Testing effectiveness (Phase 2)Study completedNCT04220866
What this trial is testing
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Merck Sharp & Dohme LLC 18